Tearsheet
AORT Home Investment Highlights Valuation, Metrics & Events Price Chart Why The Stock Moved Return vs. Risk About AORT Interactive Breakdown Better Bets vs. AORT Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Trade Sentinel Industry Resource Links External Quote Links

Artivion (AORT)

Market Price (2/17/2026): $36.495 | Market Cap: $1.7 Bil
Sector: Health Care | Industry: Health Care Equipment

Artivion (AORT)

Market Price (2/17/2026): $36.495
Market Cap: $1.7 Bil
Sector: Health Care
Industry: Health Care Equipment

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0 Low stock price volatility
Vol 12M is 43%		 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 77x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 57x
1 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease. Themes include Geriatric Care, Cardiovascular Device Therapy, and Surgical Implants. 		Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -4.8%
2  Key risks
AORT key risks include [1] high financial leverage, Show more.
0 Low stock price volatility
Vol 12M is 43%
1 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease. Themes include Geriatric Care, Cardiovascular Device Therapy, and Surgical Implants.
2 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 77x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 57x
3 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -4.8%
4 Key risks
AORT key risks include [1] high financial leverage, Show more.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Artivion (AORT) stock has lost about 20% since 10/31/2025 because of the following key factors:

1. Fourth Quarter 2025 Revenue Miss. Artivion reported revenues of $116 million for the fourth quarter of 2025, which fell slightly short of Wall Street analysts' consensus estimates, often cited as around $117 million or $116.42 million. Despite reporting adjusted earnings per share (EPS) that were in line with or exceeded expectations, the top-line miss likely triggered a negative market reaction, leading to a decline in share price.

2. Softness in Tissue Processing and BioGlue Sales. The company's management indicated that subdued revenue from tissue processing, partly due to the lingering effects of a previous cybersecurity incident, and flat sales from BioGlue, attributed to variability in distributor stocking, contributed to the overall revenue shortfall in Q4 2025. While other segments like stent grafts and On-X valves showed strong growth, these weaker areas impacted the overall financial performance against expectations.

Show more

Stock Movement Drivers

Fundamental Drivers

The -19.6% change in AORT stock from 10/31/2025 to 2/17/2026 was primarily driven by a -17.8% change in the company's P/S Multiple.
(LTM values as of)103120252172026Change
Stock Price ($)45.3736.49-19.6%
Change Contribution By: 
Total Revenues ($ Mil)4054234.3%
P/S Multiple5.04.1-17.8%
Shares Outstanding (Mil)4447-6.2%
Cumulative Contribution-19.6%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 2/17/2026
ReturnCorrelation
AORT-19.6% 
Market (SPY)0.1%16.4%
Sector (XLV)9.1%25.7%

Fundamental Drivers

The 18.1% change in AORT stock from 7/31/2025 to 2/17/2026 was primarily driven by a 21.9% change in the company's P/S Multiple.
(LTM values as of)73120252172026Change
Stock Price ($)30.9136.4918.1%
Change Contribution By: 
Total Revenues ($ Mil)3904238.3%
P/S Multiple3.34.121.9%
Shares Outstanding (Mil)4247-10.6%
Cumulative Contribution18.1%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2025 to 2/17/2026
ReturnCorrelation
AORT18.1% 
Market (SPY)8.3%21.5%
Sector (XLV)21.2%23.5%

Fundamental Drivers

The 17.9% change in AORT stock from 1/31/2025 to 2/17/2026 was primarily driven by a 21.2% change in the company's P/S Multiple.
(LTM values as of)13120252172026Change
Stock Price ($)30.9636.4917.9%
Change Contribution By: 
Total Revenues ($ Mil)3854239.8%
P/S Multiple3.44.121.2%
Shares Outstanding (Mil)4247-11.4%
Cumulative Contribution17.9%

LTM = Last Twelve Months as of date shown

Market Drivers

1/31/2025 to 2/17/2026
ReturnCorrelation
AORT17.9% 
Market (SPY)14.5%31.5%
Sector (XLV)8.6%20.5%

Fundamental Drivers

The 179.9% change in AORT stock from 1/31/2023 to 2/17/2026 was primarily driven by a 144.7% change in the company's P/S Multiple.
(LTM values as of)13120232172026Change
Stock Price ($)13.0436.49179.9%
Change Contribution By: 
Total Revenues ($ Mil)31442334.7%
P/S Multiple1.74.1144.7%
Shares Outstanding (Mil)4047-15.1%
Cumulative Contribution179.9%

LTM = Last Twelve Months as of date shown

Market Drivers

1/31/2023 to 2/17/2026
ReturnCorrelation
AORT179.9% 
Market (SPY)74.2%36.1%
Sector (XLV)23.5%29.5%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
AORT Return-14%-40%48%60%60%-20%55%
Peers Return18%-14%6%10%21%-4%38%
S&P 500 Return27%-19%24%23%16%-0%82%

Monthly Win Rates [3]
AORT Win Rate33%42%67%50%50%0% 
Peers Win Rate55%47%52%62%65%40% 
S&P 500 Win Rate75%42%67%75%67%50% 

Max Drawdowns [4]
AORT Max Drawdown-27%-51%-3%-7%-22%-20% 
Peers Max Drawdown-7%-25%-12%-8%-2%-10% 
S&P 500 Max Drawdown-1%-25%-1%-2%-15%-1% 

[1] Cumulative total returns since the beginning of 2021
[2] Peers: MDT, EW, ABT, BSX, JNJ.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/17/2026 (YTD)

How Low Can It Go

Unique KeyEventAORTS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-68.8%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven220.4%34.1%
2022 Inflation ShockTime to BreakevenTime to Breakeven989 days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-52.0%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven108.5%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven409 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-37.2%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven59.2%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven2,108 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-75.5%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven308.8%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven2,728 days1,480 days

Compare to MDT, EW, ABT, BSX, JNJ

In The Past

Artivion's stock fell -68.8% during the 2022 Inflation Shock from a high on 5/6/2021. A -68.8% loss requires a 220.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Artivion (AORT)

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

AI Analysis | Feedback

  • The Medtronic of aortic repair.
  • Edwards Lifesciences for the entire aorta.

AI Analysis | Feedback

  • Perceval Sutureless Heart Valve: A device for aortic valve replacement that eliminates the need for sutures, simplifying the surgical procedure.
  • On-X Mechanical Heart Valves: Prosthetic heart valves designed for long-term replacement of the aortic or mitral valve.
  • E-vita OPEN NEO: A hybrid stent graft system used for the simultaneous treatment of the ascending aorta and aortic arch.
  • BioGlue Surgical Adhesive: A surgical sealant used to reinforce suture lines and achieve hemostasis in cardiovascular and vascular procedures.
  • ENDOCARE and NEXUS Endovascular Stent Grafts: Devices designed for the minimally invasive repair of thoracic aortic aneurysms and dissections.

AI Analysis | Feedback

Major Customers of Artivion (AORT)

Artivion, Inc. (AORT) sells primarily to other companies and organizations within the healthcare industry.

While Artivion's medical devices and allografts are ultimately used by cardiac and vascular surgeons in thousands of hospitals and clinics worldwide, the direct purchasers and key entities in their sales channels can be categorized as follows:

  • Hospitals and Healthcare Systems: These are the primary end-users and direct purchasers of Artivion's products. Artivion sells to numerous individual hospitals, many of which are part of larger healthcare systems that manage purchasing. Examples of large public healthcare systems that operate hospitals which purchase medical devices include:

    • HCA Healthcare (Symbol: HCA)
    • Tenet Healthcare Corporation (Symbol: THC)

  • Group Purchasing Organizations (GPOs): GPOs play a significant role in the healthcare supply chain by negotiating contracts for medical devices on behalf of their member hospitals and healthcare providers. Artivion enters into agreements with GPOs to make its products available to a broad network of healthcare facilities. An example of a public GPO is:

    • Premier, Inc. (Symbol: PINC)

  • Third-Party Distributors: Especially in international markets or regions where Artivion does not have a direct sales force, the company sells its products to third-party distributors. These distributors then resell the products to hospitals, clinics, and other healthcare providers. Major public healthcare distributors include:

    • Cardinal Health, Inc. (Symbol: CAH)
    • McKesson Corporation (Symbol: MCK)
    • Owens & Minor, Inc. (Symbol: OMI)

AI Analysis | Feedback

null

AI Analysis | Feedback

J. Patrick Mackin, Chairman, President, and Chief Executive Officer

Mr. Mackin joined Artivion in September 2014 and was appointed Chairman in April 2015. He brings over 30 years of experience in the medical device industry. Prior to Artivion, he served as President of Cardiac Rhythm Disease Management, the largest operating division of Medtronic, Inc., and held senior leadership positions at Genzyme.

Lance A. Berry, Executive Vice President, Chief Operating Officer, Chief Financial Officer and Treasurer

Mr. Berry was appointed as Artivion's Chief Financial Officer on December 4, 2023. He previously served as Executive Vice President, Chief Financial and Operations Officer of Wright Medical Group N.V. from January 2019 until its acquisition by Stryker in November 2020. Before that, he was Senior Vice President, Chief Financial Officer for Wright from 2009 to 2018, where he successfully spearheaded its merger with Tornier N.V. His expertise includes strategy, M&A, and financing.

John E. Davis, Chief Commercial Officer

Mr. Davis was appointed Chief Commercial Officer in February 2024 and has over 25 years of experience in sales, marketing, and executive leadership. Prior to Artivion, he was Executive Vice President of Sales and Marketing at CorMatrix and served as a Vice President of Sales in the Cardiac Rhythm Management Devices business at St. Jude Medical.

Jean F. Holloway, Esq., Senior Vice President, General Counsel, Chief Compliance Officer and Secretary

Ms. Holloway holds the titles of Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary at Artivion.

Marshall S. Stanton, M.D., Senior Vice President, Clinical Research, and Chief Medical Officer

Dr. Stanton was appointed Senior Vice President, Clinical Research, and Chief Medical Officer in March 2021. He has over 20 years of experience in the medical device industry and more than 30 years in advancing healthcare. Before joining Artivion, he held various senior management positions at Medtronic, Inc., including Senior Vice President and President of the Pain Therapies Business Unit. Dr. Stanton is scheduled to retire effective March 31, 2026.

AI Analysis | Feedback

Key Risks to Artivion (AORT) Business

Artivion (NYSE: AORT) faces several notable risks to its business operations and financial performance. These risks primarily revolve around its financial leverage, the intricate process of regulatory approvals and product adoption for its new medical devices, and the potential for cybersecurity incidents.

1. Financial Leverage and Debt

Artivion's financial position carries a degree of risk due to its debt load. The company's interest coverage is notably weak, suggesting high leverage, and a past drop in EBIT indicates that managing this debt could be challenging if profitability continues to decline. While Artivion has taken steps to improve its balance sheet, such as converting convertible debt into shares, the overall debt level remains a significant factor for investors.

2. Regulatory Approvals and Market Adoption of New Products

A critical aspect of Artivion's growth strategy hinges on the successful and timely regulatory approval of its pipeline products, such as AMDS and NEXUS, and their subsequent adoption by hospitals and surgeons. Any delays in the regulatory process or a lukewarm market reception of these new devices could significantly impact the company's projected growth and financial performance. The unpredictability of regulatory decisions is a consistently cited risk factor in their financial filings.

3. Cybersecurity Incidents and Supply Chain Disruptions

Artivion has demonstrated vulnerability to cybersecurity incidents, as evidenced by a November 2024 cyberattack that negatively affected its Q4 2024 results and continued to impact preservation services into Q1 2025. Although recovery efforts are underway, such incidents highlight an ongoing risk of operational disruptions, potential data breaches, and adverse effects on supply chain and service delivery.

AI Analysis | Feedback

null

AI Analysis | Feedback

Here's an overview of the addressable markets for Artivion's (AORT) main products and services: Artivion operates within the cardiac and vascular surgery market, focusing on aortic disease. The company's total addressable market (TAM) is estimated to be over $5.3 billion globally. Key products and their addressable markets include:
  • Ascyrus Medical Dissection Stent (AMDS): For the treatment of acute DeBakey Type I aortic dissections, the addressable market in the U.S. is an estimated $150 million annually.
  • On-X Mechanical Heart Valves: Artivion is pursuing a new $100 million annual market opportunity in the U.S. for its On-X heart valve, driven by new clinical data. Globally, the prosthetic heart valve market was valued at $9.64 billion in 2024 and is projected to reach $20.69 billion by 2033. Aortic procedures constituted 56.53% of this market in 2024. North America held the largest share of the global prosthetic heart valve market in 2024, at 48.5%.
Artivion's product pipeline also presents a $1 billion market opportunity for new and next-generation products focusing on aortic repair, which is likely a global estimate given the company's international operations. The company's diverse portfolio addresses a wide range of aortic diseases, including heart valve disease, aortic aneurysms, and dissections, serving regions across North America, EMEA, APAC, and LATAM. The PerClot Absorbable Hemostatic System, while previously a product of Artivion, had its product line and FDA approval transferred to Baxter International, Inc., indicating it is no longer a primary addressable market for Artivion.

AI Analysis | Feedback

Artivion (AORT) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and product performances:

  1. Continued Adoption and Expansion of AMDS: The successful launch and growing adoption of the AMDS (Aortic Modular Stent Graft) in the U.S. is a significant driver. Stent graft revenues, largely fueled by AMDS, increased by 31% on a constant currency basis in Q3 2025. The company also anticipates sequential growth in AMDS sales throughout 2025. A new reimbursement code (MSDRG DRG-209), effective October 1, 2025, is expected to provide a tailwind by increasing reimbursement for advanced aortic arch procedures, thereby reducing cost constraints for healthcare providers and further supporting AMDS adoption. Artivion plans to submit PMA applications for AMDS with a target for PMA approval in mid-2026.
  2. Global Market Share Gains and Growth of On-X Heart Valve: The On-X heart valve business has demonstrated exceptional growth, with a 23% increase in revenue in Q3 2025 and 24% year-over-year growth in Q2 2025 on a constant currency basis. This growth is attributed to its unique clinical profile, including its low INR indication from the FDA, and continued market share gains globally, particularly for patients under 65. Artivion is actively educating healthcare providers on clinical data demonstrating the mortality benefit of On-X in certain patient populations.
  3. Launch and Commercialization of Nexus: Artivion has a robust product pipeline, with Nexus identified as a promising product expected to unlock significant market opportunities. The company is optimistic about Nexus's approval in the second half of 2026 and has made financial arrangements, including a $150 million delayed draw term loan, to acquire Endospan following FDA approval, which would grant access to an estimated $150 million annual U.S. market opportunity. One-year clinical data from the Nexus trial is expected to be presented in January 2026.
  4. Geographic Expansion, particularly in North America and Asia Pacific: Artivion has shown strong regional revenue growth, with North America increasing by 19% and Asia Pacific by 18% in Q3 2025. This indicates successful market penetration and presents opportunities for continued growth in these regions through increased sales and adoption of their product portfolio.

AI Analysis | Feedback

Share Issuance

  • In May 2025, Artivion completed agreements to exchange approximately $99.54 million in principal amount of its 4.250% Convertible Senior Notes due 2025 for 4,334,347 shares of common stock.
  • In August 2025, Artivion registered 3,570,000 additional shares of common stock for issuance under its 2020 Equity and Cash Incentive Plan, following Board and stockholder approval in March and May 2025, respectively.
  • The number of issued shares increased by 758,000 during Q1 2025, from 43.432 million as of December 31, 2024, to 44.190 million as of March 31, 2025.

Outbound Investments

  • Artivion's capital allocation strategy in September 2025 was focused on the planned acquisition of Endospan.

Capital Expenditures

  • Capital expenditures for Q2 2025 were $3.287 million, and $6.925 million year-to-date Q2 2025.
  • Artivion's capital expenditures average $2 million to $3.6 million per quarter, primarily supporting asset base maintenance.
  • Ongoing research and development (R&D) investments, approximately 7% to 8% of revenue, are crucial for maintaining competitive advantage.

Better Bets vs. Artivion (AORT)

Latest Trefis Analyses

TitleDate
0DASHBOARDS 
1Artivion Earnings Notes12/20/2025
2Would You Still Hold Artivion Stock If It Fell 30%?10/17/2025
3AORT Stock in Focus: Does It Outshine the Peer Group?08/22/2025
4Better Bet Than AORT Stock: Pay Less Than Artivion To Get More From PEN, PODD 08/21/2025
5Day 8 of Gains Streak for Artivion Stock with 42% Return (vs. 53% YTD) [8/12/2025]08/13/2025
6Day 7 of Gains Streak for Artivion Stock with 39% Return (vs. 50% YTD) [8/11/2025]08/12/2025
7Day 6 of Gains Streak for Artivion Stock with 32% Return (vs. 43% YTD) [8/8/2025]08/09/2025
8Why Artivion Stock Moved: AORT Stock Has Gained 284% Since 2022 Fiscal End, Primarily Due To Favorable Change In Price To Sales Multiple (P/S)08/08/2025
9AORT Dip Buy Analysis07/10/2025
10Should You Buy Artivion Stock?05/16/2025
11ARTICLES 
12Small Cap Stocks Trading At 52-Week High11/06/2025
13AORT vs the Competition: Which Stock Comes Out on Top?08/21/2025
14Better Bet Than Artivion Stock: Pay Less To Get More From PEN, PODD08/21/2025
15AORT Stock Up 42% after 8-Day Win Streak08/13/2025
16AORT Stock Up 39% after 7-Day Win Streak08/12/2025
Title
0DASHBOARDS
1Artivion Earnings Notes
2Would You Still Hold Artivion Stock If It Fell 30%?
3AORT Stock in Focus: Does It Outshine the Peer Group?
4Better Bet Than AORT Stock: Pay Less Than Artivion To Get More From PEN, PODD 
5Day 8 of Gains Streak for Artivion Stock with 42% Return (vs. 53% YTD) [8/12/2025]
6Day 7 of Gains Streak for Artivion Stock with 39% Return (vs. 50% YTD) [8/11/2025]
7Day 6 of Gains Streak for Artivion Stock with 32% Return (vs. 43% YTD) [8/8/2025]
8Why Artivion Stock Moved: AORT Stock Has Gained 284% Since 2022 Fiscal End, Primarily Due To Favorable Change In Price To Sales Multiple (P/S)
9AORT Dip Buy Analysis
10Should You Buy Artivion Stock?
11ARTICLES
12Small Cap Stocks Trading At 52-Week High
13AORT vs the Competition: Which Stock Comes Out on Top?
14Better Bet Than Artivion Stock: Pay Less To Get More From PEN, PODD
15AORT Stock Up 42% after 8-Day Win Streak
16AORT Stock Up 39% after 7-Day Win Streak

Trade Ideas

Select ideas related to AORT.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
VEEV_1302026_Monopoly_xInd_xCD_Getting_Cheaper01302026VEEVVeeva SystemsMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-14.6%-14.6%-15.7%
BIIB_1162026_Dip_Buyer_FCFYield01162026BIIBBiogenDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		19.5%19.5%0.0%
BMRN_1162026_Dip_Buyer_FCFYield01162026BMRNBioMarin PharmaceuticalDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		9.7%9.7%0.0%
DOCS_1162026_Dip_Buyer_High_CFO_Margins_ExInd_DE01162026DOCSDoximityDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap		-39.4%-39.4%-40.1%
CORT_1022026_Dip_Buyer_High_CFO_Margins_ExInd_DE01022026CORTCorcept TherapeuticsDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap		4.6%4.6%-9.1%

Recent Active Movers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Peers to compare with:

Financials

AORTMDTEWABTBSXJNJMedian
NameArtivion MedtronicEdwards .Abbott L.Boston S.Johnson . 
Mkt Price36.4996.7978.43112.2076.28243.3787.61
Mkt Cap1.7124.145.9195.5113.0586.0118.6
Rev LTM42334,7585,88443,84319,35094,19327,054
Op Inc LTM226,7191,6197,7133,72025,5965,220
FCF LTM185,2068006,9173,62819,3134,417
FCF 3Y Avg84,9176885,9652,37818,3833,648
CFO LTM307,1131,0179,1194,62624,5305,870
CFO 3Y Avg206,6269558,1323,30523,8624,966

Growth & Margins

AORTMDTEWABTBSXJNJMedian
NameArtivion MedtronicEdwards .Abbott L.Boston S.Johnson . 
Rev Chg LTM9.8%5.3%10.6%6.4%21.6%6.0%8.1%
Rev Chg 3Y Avg10.5%4.1%4.4%-0.6%15.6%2.6%4.3%
Rev Chg Q18.4%6.6%14.7%6.9%20.3%9.1%11.9%
QoQ Delta Rev Chg LTM4.3%1.6%3.5%1.7%4.6%2.2%2.9%
Op Mgn LTM5.3%19.3%27.5%17.6%19.2%27.2%19.3%
Op Mgn 3Y Avg4.4%18.6%28.9%16.3%18.0%25.6%18.3%
QoQ Delta Op Mgn LTM0.9%-0.1%-0.4%0.2%0.9%1.5%0.5%
CFO/Rev LTM7.2%20.5%17.3%20.8%23.9%26.0%20.6%
CFO/Rev 3Y Avg5.2%19.9%18.7%19.5%19.8%26.7%19.6%
FCF/Rev LTM4.1%15.0%13.6%15.8%18.7%20.5%15.4%
FCF/Rev 3Y Avg2.0%14.8%13.4%14.3%14.1%20.6%14.2%

Valuation

AORTMDTEWABTBSXJNJMedian
NameArtivion MedtronicEdwards .Abbott L.Boston S.Johnson . 
Mkt Cap1.7124.145.9195.5113.0586.0118.6
P/S4.13.67.84.55.86.25.1
P/EBIT76.819.426.922.631.317.524.7
P/E-188.626.033.614.040.521.924.0
P/CFO56.617.445.121.424.423.924.2
Total Yield-0.5%6.8%3.0%9.2%2.5%6.7%4.8%
Dividend Yield0.0%2.9%0.0%2.1%0.0%2.1%1.0%
FCF Yield 3Y Avg0.4%4.4%1.5%2.9%2.0%4.6%2.5%
D/E0.20.20.00.10.10.10.1
Net D/E0.10.2-0.10.00.10.00.1

Returns

AORTMDTEWABTBSXJNJMedian
NameArtivion MedtronicEdwards .Abbott L.Boston S.Johnson . 
1M Rtn-15.9%0.0%-7.0%-7.9%-13.4%11.3%-7.4%
3M Rtn-18.6%-3.3%-6.7%-13.3%-23.1%21.7%-10.0%
6M Rtn-13.1%9.3%-0.6%-13.7%-26.5%38.8%-6.9%
12M Rtn21.4%7.6%2.9%-12.5%-28.1%60.6%5.3%
3Y Rtn161.4%25.9%-0.1%11.5%63.9%65.0%44.9%
1M Excs Rtn-14.2%-0.8%-5.7%-7.7%-13.8%12.3%-6.7%
3M Excs Rtn-21.5%-0.2%-10.5%-14.3%-28.9%23.9%-12.4%
6M Excs Rtn-20.9%-0.5%-5.9%-20.1%-32.2%33.6%-13.0%
12M Excs Rtn9.2%-3.7%-8.7%-25.2%-40.0%47.6%-6.2%
3Y Excs Rtn105.5%-40.3%-66.2%-57.5%-5.6%-2.5%-22.9%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil2024202320222021
Medical devices230222179197
Preservation services83777479
Total314299253276


Price Behavior

Price Behavior
Market Price$36.50 
Market Cap ($ Bil)1.7 
First Trading Date12/29/2006 
Distance from 52W High-23.4% 
   50 Days200 Days
DMA Price$43.41$38.70
DMA Trendupdown
Distance from DMA-15.9%-5.7%
 3M1YR
Volatility31.1%42.8%
Downside Capture71.5147.44
Upside Capture-57.9361.33
Correlation (SPY)13.4%31.1%
AORT Betas & Captures as of 1/31/2026

 1M2M3M6M1Y3Y
Beta0.160.070.571.000.710.97
Up Beta3.892.741.752.950.880.96
Down Beta-0.33-0.710.120.160.520.84
Up Capture-145%-60%8%103%65%156%
Bmk +ve Days11223471142430
Stock +ve Days9183064120381
Down Capture89%69%80%46%67%98%
Bmk -ve Days9192754109321
Stock -ve Days11233159127361

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with AORT
AORT23.4%42.7%0.60-
Sector ETF (XLV)9.0%17.4%0.3419.9%
Equity (SPY)13.0%19.4%0.5131.0%
Gold (GLD)67.2%25.5%1.991.1%
Commodities (DBC)5.2%16.8%0.137.4%
Real Estate (VNQ)7.8%16.6%0.2818.9%
Bitcoin (BTCUSD)-28.8%44.9%-0.6212.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with AORT
AORT7.6%43.9%0.31-
Sector ETF (XLV)7.9%14.5%0.3632.9%
Equity (SPY)13.3%17.0%0.6239.4%
Gold (GLD)21.3%17.1%1.027.2%
Commodities (DBC)10.2%18.9%0.426.2%
Real Estate (VNQ)5.3%18.8%0.1936.4%
Bitcoin (BTCUSD)8.2%57.2%0.3618.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with AORT
AORT14.8%43.5%0.47-
Sector ETF (XLV)11.3%16.5%0.5740.2%
Equity (SPY)15.8%17.9%0.7643.5%
Gold (GLD)14.8%15.6%0.793.3%
Commodities (DBC)8.0%17.6%0.3711.8%
Real Estate (VNQ)6.8%20.7%0.2937.1%
Bitcoin (BTCUSD)68.5%66.7%1.0811.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date1302026
Short Interest: Shares Quantity1.6 Mil
Short Interest: % Change Since 11520262.6%
Average Daily Volume0.3 Mil
Days-to-Cover Short Interest5.2 days
Basic Shares Quantity47.2 Mil
Short % of Basic Shares3.5%

Returns Analyses

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
2/12/2026-10.0%  
11/6/2025-5.5%-4.0%-8.9%
8/7/202525.2%31.3%32.8%
5/5/202515.4%21.0%20.6%
2/24/2025-8.2%-9.8%-11.4%
11/7/2024-0.9%-6.9%0.1%
8/8/2024-1.9%-0.4%-3.9%
5/6/202412.8%10.1%11.2%
...
SUMMARY STATS   
# Positive101414
# Negative151010
Median Positive11.3%10.2%14.3%
Median Negative-1.9%-3.0%-7.4%
Max Positive25.2%36.5%39.8%
Max Negative-10.0%-17.9%-38.2%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202511/07/202510-Q
06/30/202508/08/202510-Q
03/31/202505/06/202510-Q
12/31/202402/28/202510-K
09/30/202411/08/202410-Q
06/30/202408/09/202410-Q
03/31/202405/07/202410-Q
12/31/202302/23/202410-K
09/30/202311/03/202310-Q
06/30/202308/04/202310-Q
03/31/202305/05/202310-Q
12/31/202202/23/202310-K
09/30/202211/04/202210-Q
06/30/202208/05/202210-Q
03/31/202205/06/202210-Q
12/31/202102/22/202210-K

Insider Activity

Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value		Value of
Held Shares		Form
1Davis, John EChief Commercial OfficerDirectSell1217202545.115,000225,5508,744,213Form
2Horton, AmyVP, Chief Accounting OfficerDirectSell1209202544.424,572203,0845,777,046Form
3MacKin, James PPresident & CEODirectSell1204202545.4630,9211,405,70036,413,943Form
4Holloway, Jean FSVP, General CounselDirectSell1204202545.307,315331,3707,071,013Form
5MacKin, James PPresident & CEODirectSell1203202545.5630,9211,408,73036,492,440Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.